Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

20.42 -0.69 (-3.27%)
Streaming Delayed Price Updated: 1:27 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
WHY: NEW YORK, NY - (NewMediaWire) - February 06, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
WHY: NEW YORK, NY - (NewMediaWire) - February 06, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
3 small-cap biotechs with potential breakthroughs in 2024
These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024. 
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
Cassava ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Is There Any Hope for Cassava Sciences Stock?
Battered by controversy, this company will need to show real results to prosper. 
Via The Motley Fool
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
From The Rosen Law Firm, P.A.
Via Business Wire
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
(SAVA) - Analyzing Cassava Sciences's Short Interest
Via Benzinga
3 Biotech Stocks to Sell in January Before They Crash and Burn
The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell. 
Via InvestorPlace
Cassava Sciences Stock Continues Showing Rising Relative Strength
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Portfolio Protection: 7 Risky Stocks to Drop Right Now
Ahead of further or unforeseen challenges, if you own any of these seven risky stocks, now's the time to bail. 
Via InvestorPlace
New SAVAW Warrants Are Trading After Cassava Sciences’ Distribution
Following a distribution, investors in Cassava Sciences and SAVA stock now have some warrants to factor into their models today. 
Via InvestorPlace
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
From Cassava Sciences, Inc.
Via GlobeNewswire
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street
Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year. 
Via The Motley Fool
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
Paychex Reports Downbeat Sales, Joins BlackBerry And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones index gaining around 200 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Cassava Sciences Stock Zoomed 21% Higher This Week
The company has chosen an offbeat way to keep its investors sweet. 
Via The Motley Fool
Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days
Cassava Sciences sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
Although Cassava Sciences’ issuance of warrants presents risks, the underlying Phase 3 trial support boosted SAVA stock. 
Via InvestorPlace
Blue Bird Posts Upbeat Results, Joins Oil-Dri Corporation of America, Eagle Bulk Shipping And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
From Cassava Sciences, Inc.
Via GlobeNewswire
What's Going On With Cassava Sciences Stock?
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher Monday on continued upward momentum. The stock has gained more than 20% over than last five days. What To Know: 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
High short interest stocks: this popular trend is re-emerging
Renewed optimism has led to higher risk tolerance in stocks, which has brought back a popular trend: Stocks with high short interest are gaining popularity 
Via MarketBeat
Topics ETFs
Why Cassava Sciences Stock Soared Today
Investors cheered the arrival of a trio of new board members. 
Via The Motley Fool
Cassava Sciences Appoints Three New Members to its Board of Directors
Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government 
From Cassava Sciences, Inc.
Via GlobeNewswire
7 High-Risk, High-Reward Stocks for the Extreme Contrarian
While most folks should stick on the established road, these stock picks for contrarian investors might tempt the intrepid. 
Via InvestorPlace
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.